Malignant Head and Neck Neoplasm

cancer family

Identifier: CI-CAN-00000236
Entity page: /cancer/malignant-head-and-neck-neoplasm ↗
Edges: 5,996

Neighbours: 18 genes4 variants28 drugs10 trials
Drawn: 60 of 60 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Head and Neck Neoplasm approved for …APPROVED_FOR33 of 32show fewer
← approved for	Cetuximabmonoclonal_antibody	supports	EMA indication text	Malignant Head and Neck Neoplasm	1	Regulatory	ema	graph →
← approved for	Docetaxelsmall molecule

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

RET Mutation SelpercatinibFDA US 2020-05-086 active / 8 trials
Curatedlevel Asensitivity· support 3civicObservedRET altered in 2.2% (23 / 1,049 cases)Regulatoryapproved for Thyroid Gland Medullary Carcinoma (7 approval records)context: Thyroid Gland Medullary Carcinoma
RET Fusion SelpercatinibFDA US 2020-05-086 active / 8 trials
Curatedlevel Asensitivity· support 2civicObservedRET altered in 2.2% (23 / 1,049 cases)Regulatoryapproved for Thyroid Gland Medullary Carcinoma (7 approval records)context: Malignant Thyroid Gland Neoplasm, Thyroid Gland Papillary Carcinoma
RET M918T SelpercatinibFDA US 2020-05-086 active / 8 trials
Curatedlevel Asensitivity· support 2civicObservedRET altered in 2.2% (23 / 1,049 cases)Regulatoryapproved for Thyroid Gland Medullary Carcinoma (7 approval records)context: Thyroid Gland Medullary Carcinoma
RET Fusion PralsetinibFDA US 2020-09-042 active / 5 trials
Curatedlevel Asensitivity· support 1civicObservedRET altered in 2.2% (23 / 1,049 cases)Regulatoryapproved for Malignant Thyroid Gland Neoplasmcontext: Malignant Thyroid Gland Neoplasm
BRAF V600E Vemurafenib4 active / 7 trials
Curatedlevel Bsensitivity· support 6civicObservedBRAF altered in 60% (302 / 507 cases, largest of 5 cohorts)no approval record in this cancercontext: Thyroid Gland Anaplastic Carcinoma, Laryngeal Squamous Cell Carcinoma, Thyroid Gland Papillary Carcinoma
CDKN2A p16 Expression Panitumumab3 active / 15 trials
Curatedlevel Bsensitivity· support 1civicObservedCDKN2A altered in 73% (384 / 528 cases, largest of 5 cohorts)no approval record in this cancercontext: Head and Neck Squamous Cell Carcinoma
BRAF V600E DabrafenibFDA US 2013-05-297 active / 11 trials
Curatedlevel Bsensitivity· support 1civicObservedBRAF altered in 60% (302 / 507 cases, largest of 5 cohorts)Regulatoryapproved for Thyroid Gland Anaplastic Carcinoma (4 approval records)context: Thyroid Gland Anaplastic Carcinoma
BRAF V600E TrametinibFDA US 2013-05-299 active / 16 trials
Curatedlevel Bsensitivity· support 1civicObservedBRAF altered in 60% (302 / 507 cases, largest of 5 cohorts)Regulatoryapproved for Thyroid Gland Anaplastic Carcinoma (4 approval records)context: Thyroid Gland Anaplastic Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Head and Neck Neoplasm predicts response to …PREDICTS_RESPONSE_TO5 of 5
in context · predicts response to	MET R1004GSNV → predicts response to Crizotinib	sensitivity	C	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →
in context · predicts response to	PIK3CA H1047RSNV → predicts response to Dactolisib 3 source records aggregated	sensitivity	D	Malignant Head and Neck Neoplasm	3	Curated	civic	graph →
in context · predicts response to	PIK3CA H1047RSNV → predicts response to Alpelisib	sensitivity	D	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →
in context · predicts response to	PIK3CA H1047RSNV → predicts response to Cetuximab	sensitivity	D	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →
in context · predicts response to	PIK3CA Mutationother → predicts response to Dactolisib	sensitivity	D	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →

Malignant Head and Neck Neoplasm prognostic in …PROGNOSTIC_IN1 of 1
← prognostic in	MDM2 SNP309	supports	B	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →

Malignant Head and Neck Neoplasm associated with …ASSOCIATED_WITH3 of 3
← associated with	MDM2	supports	B	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →
← associated with	MET	supports	C	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →
← associated with	PIK3CA 5 source records aggregated	supports	D	Malignant Head and Neck Neoplasm	5	Curated	civic	graph →

Malignant Head and Neck Neoplasm investigated for …INVESTIGATED_FOR4 of 4
← investigated for	Crizotinibsmall_molecule	supports	C	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →
← investigated for	Dactolisibsmall_molecule 4 source records aggregated	supports	D	Malignant Head and Neck Neoplasm	4	Curated	civic	graph →
← investigated for	Alpelisibsmall_molecule	supports	D	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →
← investigated for	Cetuximabmonoclonal_antibody	supports	D	Malignant Head and Neck Neoplasm	1	Curated	civic	graph →

Malignant Head and Neck Neoplasm altered in cohorts of …ALTERED_INderived15 of 428show all (up to 200)
← altered in cohorts of	CSMD3 387 / 528 cases (73 %) · ssm · TCGA-HNSC · largest of 5 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	5	Observed	gdc	graph →
← altered in cohorts of	CDKN2A 384 / 528 cases (73 %) · ssm · TCGA-HNSC · largest of 5 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	5	Observed	gdc	graph →
← altered in cohorts of	FAM135B 383 / 528 cases (73 %) · ssm · TCGA-HNSC · largest of 5 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	5	Observed	gdc	graph →
← altered in cohorts of	PLD1 377 / 528 cases (71 %) · ssm · TCGA-HNSC	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	COL22A1 376 / 528 cases (71 %) · ssm · TCGA-HNSC · largest of 4 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	4	Observed	gdc	graph →
← altered in cohorts of	CLDN16 374 / 528 cases (71 %) · ssm · TCGA-HNSC	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BCL6 373 / 528 cases (71 %) · ssm · TCGA-HNSC	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	IL1RAP 373 / 528 cases (71 %) · ssm · TCGA-HNSC	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MB21D2 373 / 528 cases (71 %) · ssm · TCGA-HNSC	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PKHD1L1 373 / 528 cases (71 %) · ssm · TCGA-HNSC · largest of 5 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	5	Observed	gdc	graph →
← altered in cohorts of	SI 373 / 528 cases (71 %) · ssm · TCGA-HNSC · largest of 5 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	5	Observed	gdc	graph →
← altered in cohorts of	TP63 373 / 528 cases (71 %) · ssm · TCGA-HNSC	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	COL14A1 372 / 528 cases (70 %) · ssm · TCGA-HNSC · largest of 3 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	3	Observed	gdc	graph →
← altered in cohorts of	EIF4G1 372 / 528 cases (70 %) · ssm · TCGA-HNSC	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MUC4 372 / 528 cases (70 %) · ssm · TCGA-HNSC · largest of 2 cohorts	—	—	Head and Neck Squamous Cell Carcinoma	2	Observed	gdc	graph →

Malignant Head and Neck Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 242show all (up to 200)
→ investigated in trials for	Cisplatinsmall molecule 446 trials (141 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	446	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 249 trials (114 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	249	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal_antibody 193 trials (32 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	193	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 151 trials (33 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	151	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 146 trials (56 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	146	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 126 trials (23 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	126	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 125 trials (43 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	125	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 107 trials (43 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 85 trials (41 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	85	Observed	clinicaltrials	graph →
→ investigated in trials for	Toripalimabmonoclonal antibody 51 trials (38 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	51	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 50 trials (19 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	50	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 40 trials (23 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 39 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 37 trials (11 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 35 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Head and Neck Neoplasm	35	Observed	clinicaltrials	graph →

Malignant Head and Neck Neoplasm studied in …STUDIED_INderived10 of 5,281show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 5,281 trials mapped (1,721 active)	—	—	Head and Neck Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03358472Phase 3 · completed Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) · condition mapped ALIAS · 5,281 trials mapped (1,721 active)	—	—	Malignant Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04085900recruiting Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City · condition mapped ONTOLOGY_EXACT · 5,281 trials mapped (1,721 active)	—	—	Nasopharyngeal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04890834NA · active not recruiting Dyadic Yoga Intervention for the Improvement of Healthcare Utilization and Quality of Life in Patients With Head and Neck Cancer Undergoing Chemoradiation and Their Caregivers · condition mapped ONTOLOGY_EXACT · 5,281 trials mapped (1,721 active)	—	—	Head and Neck Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05057247Phase 2 · completed Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC · condition mapped CURATED_BROADER · 5,281 trials mapped (1,721 active)	—	—	Malignant Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05604105not yet recruiting Oral Cancer Awareness in Egypt · condition mapped CURATED_BROADER · 5,281 trials mapped (1,721 active)	—	—	Malignant Lip and Oral Cavity Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 5,281 trials mapped (1,721 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped ONTOLOGY_EXACT · 5,281 trials mapped (1,721 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06309225NA · recruiting Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly · condition mapped ALIAS · 5,281 trials mapped (1,721 active)	—	—	Malignant Oropharyngeal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06479811Phase 1 · recruiting [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers · condition mapped ONTOLOGY_EXACT · 5,281 trials mapped (1,721 active)	—	—	Sinonasal Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →